A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 424 participants.

Also called NCT02597049

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 424 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02597049
  • EudraCT 2015-002095-24
Other papers using this trial's data
  • Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial The lancet. Diabetes & endocrinology, 2018-05 DOI, PubMed 29483060 PubMed links an erratum for this paper. Erratum: PMID 29803266

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Czechia, Germany, Hungary, Israel, Mexico, Puerto Rico, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02597049. Randomized; double masking; primary purpose treatment. Start 2015-11 (registry gives no type); primary completion 2017-02 (actual). Results posted on 2018-04-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus
Acronym
AWARD-10
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Dulaglutide
Intervention (Drug)
Placebo
Intervention (Drug)
SGLT2 inhibitor
Intervention (Drug)
Metformin
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct02597049
Content hash
585e2e52035bdab8e54ed231dbc44d9e36bd1d6ee9e6e45ddd19c35486bd7a9d